nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—SLC22A2—Vinblastine—lung cancer	0.064	0.146	CbGbCtD
Epinephrine—SLC22A2—Cisplatin—lung cancer	0.0587	0.134	CbGbCtD
Epinephrine—CYP2C9—Gefitinib—lung cancer	0.037	0.0842	CbGbCtD
Epinephrine—CYP2C9—Teniposide—lung cancer	0.0358	0.0817	CbGbCtD
Epinephrine—CYP1A2—Erlotinib—lung cancer	0.0243	0.0553	CbGbCtD
Epinephrine—CYP3A4—Topotecan—lung cancer	0.0235	0.0536	CbGbCtD
Epinephrine—CYP3A4—Gefitinib—lung cancer	0.0215	0.049	CbGbCtD
Epinephrine—CYP3A4—Teniposide—lung cancer	0.0208	0.0475	CbGbCtD
Epinephrine—CYP2C9—Paclitaxel—lung cancer	0.02	0.0456	CbGbCtD
Epinephrine—CYP1A2—Etoposide—lung cancer	0.0175	0.04	CbGbCtD
Epinephrine—CYP3A4—Vinorelbine—lung cancer	0.0166	0.0377	CbGbCtD
Epinephrine—CYP2C9—Cisplatin—lung cancer	0.0161	0.0367	CbGbCtD
Epinephrine—CYP3A4—Crizotinib—lung cancer	0.0132	0.03	CbGbCtD
Epinephrine—CYP3A4—Erlotinib—lung cancer	0.0127	0.029	CbGbCtD
Epinephrine—CYP3A4—Paclitaxel—lung cancer	0.0116	0.0265	CbGbCtD
Epinephrine—CYP3A4—Irinotecan—lung cancer	0.0115	0.0262	CbGbCtD
Epinephrine—CYP3A4—Vinblastine—lung cancer	0.0102	0.0233	CbGbCtD
Epinephrine—CYP3A4—Etoposide—lung cancer	0.00919	0.0209	CbGbCtD
Epinephrine—CYP3A4—Docetaxel—lung cancer	0.00841	0.0192	CbGbCtD
Epinephrine—CYP3A4—Doxorubicin—lung cancer	0.00627	0.0143	CbGbCtD
Epinephrine—ADRBK1—mammary gland—lung cancer	0.00335	0.143	CbGeAlD
Epinephrine—ADRBK1—respiratory system—lung cancer	0.00223	0.095	CbGeAlD
Epinephrine—TNF—lymph node—lung cancer	0.00141	0.0601	CbGeAlD
Epinephrine—ADRBK1—bone marrow—lung cancer	0.00131	0.0557	CbGeAlD
Epinephrine—ADRBK1—lung—lung cancer	0.00119	0.0504	CbGeAlD
Epinephrine—ADRA1D—epithelium—lung cancer	0.00107	0.0457	CbGeAlD
Epinephrine—SLC22A5—mammary gland—lung cancer	0.00101	0.043	CbGeAlD
Epinephrine—CYP2C9—mammary gland—lung cancer	0.00087	0.037	CbGeAlD
Epinephrine—ADRBK1—lymph node—lung cancer	0.000811	0.0345	CbGeAlD
Epinephrine—ADRB1—bronchus—lung cancer	0.000768	0.0327	CbGeAlD
Epinephrine—SLC22A5—respiratory system—lung cancer	0.000674	0.0287	CbGeAlD
Epinephrine—ADRB1—cardiac atrium—lung cancer	0.000648	0.0276	CbGeAlD
Epinephrine—Renal impairment—Paclitaxel—lung cancer	0.000625	0.00237	CcSEcCtD
Epinephrine—Lightheadedness—Docetaxel—lung cancer	0.000621	0.00236	CcSEcCtD
Epinephrine—Mental disorder—Erlotinib—lung cancer	0.00062	0.00235	CcSEcCtD
Epinephrine—Pulmonary oedema—Docetaxel—lung cancer	0.000618	0.00235	CcSEcCtD
Epinephrine—ADRA1A—epithelium—lung cancer	0.000617	0.0263	CbGeAlD
Epinephrine—Erythema—Erlotinib—lung cancer	0.000616	0.00234	CcSEcCtD
Epinephrine—Sweating increased—Irinotecan—lung cancer	0.000614	0.00233	CcSEcCtD
Epinephrine—Dizziness—Crizotinib—lung cancer	0.000612	0.00232	CcSEcCtD
Epinephrine—CYP1A2—respiratory system—lung cancer	0.000611	0.026	CbGeAlD
Epinephrine—Hypoglycaemia—Paclitaxel—lung cancer	0.000609	0.00231	CcSEcCtD
Epinephrine—Hypoaesthesia—Vinorelbine—lung cancer	0.000608	0.00231	CcSEcCtD
Epinephrine—Cerebrovascular accident—Paclitaxel—lung cancer	0.000607	0.0023	CcSEcCtD
Epinephrine—Hypokalaemia—Cisplatin—lung cancer	0.000602	0.00229	CcSEcCtD
Epinephrine—Vomiting—Crizotinib—lung cancer	0.000588	0.00223	CcSEcCtD
Epinephrine—Ventricular arrhythmia—Doxorubicin—lung cancer	0.000585	0.00222	CcSEcCtD
Epinephrine—ADRA2C—bronchus—lung cancer	0.000579	0.0246	CbGeAlD
Epinephrine—Extravasation—Methotrexate—lung cancer	0.000573	0.00218	CcSEcCtD
Epinephrine—Flushing—Vinorelbine—lung cancer	0.000567	0.00215	CcSEcCtD
Epinephrine—Dizziness—Pemetrexed—lung cancer	0.000559	0.00212	CcSEcCtD
Epinephrine—Sweating increased—Cisplatin—lung cancer	0.000557	0.00211	CcSEcCtD
Epinephrine—SLC22A5—bronchus—lung cancer	0.000555	0.0236	CbGeAlD
Epinephrine—Acute coronary syndrome—Irinotecan—lung cancer	0.000554	0.0021	CcSEcCtD
Epinephrine—Hyperglycaemia—Gemcitabine—lung cancer	0.000554	0.0021	CcSEcCtD
Epinephrine—Hypertension—Vinblastine—lung cancer	0.000553	0.0021	CcSEcCtD
Epinephrine—Renal failure—Irinotecan—lung cancer	0.000552	0.0021	CcSEcCtD
Epinephrine—Necrosis—Doxorubicin—lung cancer	0.000552	0.0021	CcSEcCtD
Epinephrine—Myocardial infarction—Irinotecan—lung cancer	0.000551	0.00209	CcSEcCtD
Epinephrine—Nausea—Crizotinib—lung cancer	0.00055	0.00209	CcSEcCtD
Epinephrine—Arrhythmia—Vinorelbine—lung cancer	0.000546	0.00207	CcSEcCtD
Epinephrine—Hypokalaemia—Paclitaxel—lung cancer	0.000541	0.00205	CcSEcCtD
Epinephrine—Acute coronary syndrome—Gemcitabine—lung cancer	0.000539	0.00205	CcSEcCtD
Epinephrine—Sweating—Irinotecan—lung cancer	0.000539	0.00204	CcSEcCtD
Epinephrine—Renal failure—Gemcitabine—lung cancer	0.000538	0.00204	CcSEcCtD
Epinephrine—Vomiting—Pemetrexed—lung cancer	0.000538	0.00204	CcSEcCtD
Epinephrine—Myocardial infarction—Gemcitabine—lung cancer	0.000536	0.00204	CcSEcCtD
Epinephrine—Vomiting—Gefitinib—lung cancer	0.000534	0.00203	CcSEcCtD
Epinephrine—Erythema—Vinorelbine—lung cancer	0.000532	0.00202	CcSEcCtD
Epinephrine—Chest pain—Topotecan—lung cancer	0.00053	0.00201	CcSEcCtD
Epinephrine—Renal impairment—Docetaxel—lung cancer	0.000529	0.00201	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.000526	0.002	CcSEcCtD
Epinephrine—Sweating—Gemcitabine—lung cancer	0.000525	0.00199	CcSEcCtD
Epinephrine—Chest pain—Erlotinib—lung cancer	0.000524	0.00199	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.000521	0.00198	CcSEcCtD
Epinephrine—ADRA2C—trachea—lung cancer	0.00052	0.0221	CbGeAlD
Epinephrine—Sweating increased—Etoposide—lung cancer	0.00051	0.00194	CcSEcCtD
Epinephrine—Haemoglobin—Irinotecan—lung cancer	0.000507	0.00192	CcSEcCtD
Epinephrine—Haemorrhage—Irinotecan—lung cancer	0.000504	0.00191	CcSEcCtD
Epinephrine—Acute coronary syndrome—Cisplatin—lung cancer	0.000503	0.00191	CcSEcCtD
Epinephrine—Nausea—Pemetrexed—lung cancer	0.000502	0.00191	CcSEcCtD
Epinephrine—Renal failure—Cisplatin—lung cancer	0.000501	0.0019	CcSEcCtD
Epinephrine—Sweating increased—Paclitaxel—lung cancer	0.000501	0.0019	CcSEcCtD
Epinephrine—Myocardial infarction—Cisplatin—lung cancer	0.0005	0.0019	CcSEcCtD
Epinephrine—Nausea—Gefitinib—lung cancer	0.000499	0.00189	CcSEcCtD
Epinephrine—SLC22A5—trachea—lung cancer	0.000498	0.0212	CbGeAlD
Epinephrine—Nervous system disorder—Topotecan—lung cancer	0.000498	0.00189	CcSEcCtD
Epinephrine—Extravasation—Doxorubicin—lung cancer	0.000497	0.00188	CcSEcCtD
Epinephrine—ADRB1—lung—lung cancer	0.000496	0.0211	CbGeAlD
Epinephrine—Haemoglobin—Gemcitabine—lung cancer	0.000494	0.00187	CcSEcCtD
Epinephrine—Skin disorder—Topotecan—lung cancer	0.000493	0.00187	CcSEcCtD
Epinephrine—Nervous system disorder—Erlotinib—lung cancer	0.000493	0.00187	CcSEcCtD
Epinephrine—Haemorrhage—Gemcitabine—lung cancer	0.000491	0.00186	CcSEcCtD
Epinephrine—Hyperhidrosis—Topotecan—lung cancer	0.000491	0.00186	CcSEcCtD
Epinephrine—ADRA2C—cardiac atrium—lung cancer	0.000488	0.0208	CbGeAlD
Epinephrine—Skin disorder—Erlotinib—lung cancer	0.000488	0.00185	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Doxorubicin—lung cancer	0.00048	0.00182	CcSEcCtD
Epinephrine—Skin exfoliation—Methotrexate—lung cancer	0.000478	0.00181	CcSEcCtD
Epinephrine—Palpitations—Vinorelbine—lung cancer	0.00047	0.00179	CcSEcCtD
Epinephrine—Paraesthesia—Vinblastine—lung cancer	0.000469	0.00178	CcSEcCtD
Epinephrine—Flushing—Irinotecan—lung cancer	0.000468	0.00178	CcSEcCtD
Epinephrine—SLC22A5—cardiac atrium—lung cancer	0.000468	0.0199	CbGeAlD
Epinephrine—Hyperglycaemia—Paclitaxel—lung cancer	0.000463	0.00176	CcSEcCtD
Epinephrine—ADRA2A—bronchus—lung cancer	0.000462	0.0197	CbGeAlD
Epinephrine—Acute coronary syndrome—Etoposide—lung cancer	0.000461	0.00175	CcSEcCtD
Epinephrine—Hypertension—Vinorelbine—lung cancer	0.00046	0.00174	CcSEcCtD
Epinephrine—Renal failure—Etoposide—lung cancer	0.000459	0.00174	CcSEcCtD
Epinephrine—Myocardial infarction—Etoposide—lung cancer	0.000458	0.00174	CcSEcCtD
Epinephrine—Paraesthesia—Topotecan—lung cancer	0.000456	0.00173	CcSEcCtD
Epinephrine—Insomnia—Erlotinib—lung cancer	0.000454	0.00172	CcSEcCtD
Epinephrine—Chest pain—Vinorelbine—lung cancer	0.000453	0.00172	CcSEcCtD
Epinephrine—Acute coronary syndrome—Paclitaxel—lung cancer	0.000452	0.00171	CcSEcCtD
Epinephrine—Arrhythmia—Irinotecan—lung cancer	0.00045	0.00171	CcSEcCtD
Epinephrine—Renal failure—Paclitaxel—lung cancer	0.00045	0.00171	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00045	0.00171	CcSEcCtD
Epinephrine—Myocardial infarction—Paclitaxel—lung cancer	0.000449	0.0017	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—lung cancer	0.000445	0.00169	CcSEcCtD
Epinephrine—Arrhythmia—Gemcitabine—lung cancer	0.000439	0.00167	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Topotecan—lung cancer	0.000438	0.00166	CcSEcCtD
Epinephrine—Vomiting—Teniposide—lung cancer	0.000436	0.00165	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Erlotinib—lung cancer	0.000434	0.00165	CcSEcCtD
Epinephrine—Erythema—Gemcitabine—lung cancer	0.000428	0.00162	CcSEcCtD
Epinephrine—Nervous system disorder—Vinorelbine—lung cancer	0.000426	0.00162	CcSEcCtD
Epinephrine—Flushing—Cisplatin—lung cancer	0.000425	0.00161	CcSEcCtD
Epinephrine—Tachycardia—Vinorelbine—lung cancer	0.000424	0.00161	CcSEcCtD
Epinephrine—Skin disorder—Vinorelbine—lung cancer	0.000422	0.0016	CcSEcCtD
Epinephrine—Hypoaesthesia—Etoposide—lung cancer	0.000417	0.00158	CcSEcCtD
Epinephrine—ADRA2A—trachea—lung cancer	0.000415	0.0177	CbGeAlD
Epinephrine—Skin exfoliation—Doxorubicin—lung cancer	0.000414	0.00157	CcSEcCtD
Epinephrine—Haemoglobin—Paclitaxel—lung cancer	0.000413	0.00157	CcSEcCtD
Epinephrine—Haemorrhage—Paclitaxel—lung cancer	0.000411	0.00156	CcSEcCtD
Epinephrine—Hypoaesthesia—Paclitaxel—lung cancer	0.000409	0.00155	CcSEcCtD
Epinephrine—Arrhythmia—Cisplatin—lung cancer	0.000409	0.00155	CcSEcCtD
Epinephrine—Nausea—Teniposide—lung cancer	0.000407	0.00154	CcSEcCtD
Epinephrine—Erythema—Cisplatin—lung cancer	0.000399	0.00151	CcSEcCtD
Epinephrine—Paraesthesia—Vinorelbine—lung cancer	0.00039	0.00148	CcSEcCtD
Epinephrine—ADRA2A—cardiac atrium—lung cancer	0.00039	0.0166	CbGeAlD
Epinephrine—Flushing—Etoposide—lung cancer	0.000389	0.00148	CcSEcCtD
Epinephrine—Pulmonary oedema—Doxorubicin—lung cancer	0.000386	0.00146	CcSEcCtD
Epinephrine—Acute coronary syndrome—Docetaxel—lung cancer	0.000383	0.00145	CcSEcCtD
Epinephrine—Renal failure—Docetaxel—lung cancer	0.000382	0.00145	CcSEcCtD
Epinephrine—Flushing—Paclitaxel—lung cancer	0.000382	0.00145	CcSEcCtD
Epinephrine—Myocardial infarction—Docetaxel—lung cancer	0.000381	0.00144	CcSEcCtD
Epinephrine—Hypertension—Irinotecan—lung cancer	0.000379	0.00144	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000375	0.00142	CcSEcCtD
Epinephrine—ADRA2C—lung—lung cancer	0.000374	0.0159	CbGeAlD
Epinephrine—Cerebrovascular accident—Methotrexate—lung cancer	0.000371	0.00141	CcSEcCtD
Epinephrine—Hypertension—Gemcitabine—lung cancer	0.000369	0.0014	CcSEcCtD
Epinephrine—Arrhythmia—Paclitaxel—lung cancer	0.000367	0.00139	CcSEcCtD
Epinephrine—Chest pain—Gemcitabine—lung cancer	0.000364	0.00138	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000362	0.00137	CcSEcCtD
Epinephrine—Mental disorder—Paclitaxel—lung cancer	0.00036	0.00137	CcSEcCtD
Epinephrine—Erythema—Paclitaxel—lung cancer	0.000358	0.00136	CcSEcCtD
Epinephrine—SLC22A5—lung—lung cancer	0.000358	0.0152	CbGeAlD
Epinephrine—Nervous system disorder—Irinotecan—lung cancer	0.000351	0.00133	CcSEcCtD
Epinephrine—Tension—Paclitaxel—lung cancer	0.000351	0.00133	CcSEcCtD
Epinephrine—Haemoglobin—Docetaxel—lung cancer	0.00035	0.00133	CcSEcCtD
Epinephrine—Haemorrhage—Docetaxel—lung cancer	0.000349	0.00132	CcSEcCtD
Epinephrine—Nervousness—Paclitaxel—lung cancer	0.000348	0.00132	CcSEcCtD
Epinephrine—Hypoaesthesia—Docetaxel—lung cancer	0.000347	0.00132	CcSEcCtD
Epinephrine—Hyperhidrosis—Irinotecan—lung cancer	0.000346	0.00131	CcSEcCtD
Epinephrine—Dizziness—Vinblastine—lung cancer	0.000346	0.00131	CcSEcCtD
Epinephrine—Nervous system disorder—Gemcitabine—lung cancer	0.000342	0.0013	CcSEcCtD
Epinephrine—Skin disorder—Gemcitabine—lung cancer	0.000339	0.00129	CcSEcCtD
Epinephrine—Hyperhidrosis—Gemcitabine—lung cancer	0.000337	0.00128	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000337	0.00128	CcSEcCtD
Epinephrine—Dizziness—Topotecan—lung cancer	0.000336	0.00127	CcSEcCtD
Epinephrine—Vomiting—Vinblastine—lung cancer	0.000332	0.00126	CcSEcCtD
Epinephrine—Dizziness—Erlotinib—lung cancer	0.000332	0.00126	CcSEcCtD
Epinephrine—Renal impairment—Doxorubicin—lung cancer	0.00033	0.00125	CcSEcCtD
Epinephrine—Agitation—Paclitaxel—lung cancer	0.000329	0.00125	CcSEcCtD
Epinephrine—CYP1A2—lung—lung cancer	0.000324	0.0138	CbGeAlD
Epinephrine—Insomnia—Irinotecan—lung cancer	0.000324	0.00123	CcSEcCtD
Epinephrine—Flushing—Docetaxel—lung cancer	0.000324	0.00123	CcSEcCtD
Epinephrine—Vomiting—Topotecan—lung cancer	0.000323	0.00123	CcSEcCtD
Epinephrine—Hypoglycaemia—Doxorubicin—lung cancer	0.000322	0.00122	CcSEcCtD
Epinephrine—Paraesthesia—Irinotecan—lung cancer	0.000322	0.00122	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—lung cancer	0.000321	0.00122	CcSEcCtD
Epinephrine—Vomiting—Erlotinib—lung cancer	0.000319	0.00121	CcSEcCtD
Epinephrine—Nervous system disorder—Cisplatin—lung cancer	0.000319	0.00121	CcSEcCtD
Epinephrine—Somnolence—Irinotecan—lung cancer	0.000319	0.00121	CcSEcCtD
Epinephrine—Tachycardia—Cisplatin—lung cancer	0.000317	0.0012	CcSEcCtD
Epinephrine—Palpitations—Paclitaxel—lung cancer	0.000316	0.0012	CcSEcCtD
Epinephrine—Skin disorder—Cisplatin—lung cancer	0.000316	0.0012	CcSEcCtD
Epinephrine—Insomnia—Gemcitabine—lung cancer	0.000316	0.0012	CcSEcCtD
Epinephrine—Hypertension—Etoposide—lung cancer	0.000315	0.0012	CcSEcCtD
Epinephrine—Hyperhidrosis—Cisplatin—lung cancer	0.000314	0.00119	CcSEcCtD
Epinephrine—Paraesthesia—Gemcitabine—lung cancer	0.000313	0.00119	CcSEcCtD
Epinephrine—Arrhythmia—Docetaxel—lung cancer	0.000311	0.00118	CcSEcCtD
Epinephrine—Chest pain—Etoposide—lung cancer	0.000311	0.00118	CcSEcCtD
Epinephrine—Nausea—Vinblastine—lung cancer	0.00031	0.00118	CcSEcCtD
Epinephrine—Somnolence—Gemcitabine—lung cancer	0.00031	0.00118	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000309	0.00117	CcSEcCtD
Epinephrine—Hypertension—Paclitaxel—lung cancer	0.000309	0.00117	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000309	0.00117	CcSEcCtD
Epinephrine—Mental disorder—Docetaxel—lung cancer	0.000305	0.00116	CcSEcCtD
Epinephrine—Chest pain—Paclitaxel—lung cancer	0.000305	0.00116	CcSEcCtD
Epinephrine—Erythema—Docetaxel—lung cancer	0.000303	0.00115	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000303	0.00115	CcSEcCtD
Epinephrine—Nausea—Topotecan—lung cancer	0.000302	0.00114	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000301	0.00114	CcSEcCtD
Epinephrine—Nausea—Erlotinib—lung cancer	0.000298	0.00113	CcSEcCtD
Epinephrine—ADRA2A—lung—lung cancer	0.000298	0.0127	CbGeAlD
Epinephrine—Paraesthesia—Cisplatin—lung cancer	0.000292	0.00111	CcSEcCtD
Epinephrine—Tachycardia—Etoposide—lung cancer	0.000291	0.0011	CcSEcCtD
Epinephrine—Skin disorder—Etoposide—lung cancer	0.000289	0.0011	CcSEcCtD
Epinephrine—Hyperhidrosis—Etoposide—lung cancer	0.000288	0.00109	CcSEcCtD
Epinephrine—Dizziness—Vinorelbine—lung cancer	0.000287	0.00109	CcSEcCtD
Epinephrine—Nervous system disorder—Paclitaxel—lung cancer	0.000287	0.00109	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—lung cancer	0.000286	0.00109	CcSEcCtD
Epinephrine—Tachycardia—Paclitaxel—lung cancer	0.000285	0.00108	CcSEcCtD
Epinephrine—Skin disorder—Paclitaxel—lung cancer	0.000284	0.00108	CcSEcCtD
Epinephrine—Hyperhidrosis—Paclitaxel—lung cancer	0.000282	0.00107	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000281	0.00107	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—lung cancer	0.00028	0.00106	CcSEcCtD
Epinephrine—Vomiting—Vinorelbine—lung cancer	0.000276	0.00105	CcSEcCtD
Epinephrine—Renal failure—Methotrexate—lung cancer	0.000275	0.00104	CcSEcCtD
Epinephrine—Sweating—Methotrexate—lung cancer	0.000268	0.00102	CcSEcCtD
Epinephrine—Palpitations—Docetaxel—lung cancer	0.000268	0.00102	CcSEcCtD
Epinephrine—Paraesthesia—Etoposide—lung cancer	0.000268	0.00102	CcSEcCtD
Epinephrine—Somnolence—Etoposide—lung cancer	0.000265	0.00101	CcSEcCtD
Epinephrine—Insomnia—Paclitaxel—lung cancer	0.000264	0.001	CcSEcCtD
Epinephrine—Paraesthesia—Paclitaxel—lung cancer	0.000262	0.000996	CcSEcCtD
Epinephrine—Hypertension—Docetaxel—lung cancer	0.000262	0.000994	CcSEcCtD
Epinephrine—Somnolence—Paclitaxel—lung cancer	0.00026	0.000986	CcSEcCtD
Epinephrine—Chest pain—Docetaxel—lung cancer	0.000258	0.000981	CcSEcCtD
Epinephrine—Nausea—Vinorelbine—lung cancer	0.000258	0.000979	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Etoposide—lung cancer	0.000257	0.000977	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000257	0.000974	CcSEcCtD
Epinephrine—ADRA2C—lymph node—lung cancer	0.000255	0.0109	CbGeAlD
Epinephrine—Haemoglobin—Methotrexate—lung cancer	0.000253	0.000958	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000252	0.000957	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—lung cancer	0.000251	0.000954	CcSEcCtD
Epinephrine—Hyperglycaemia—Doxorubicin—lung cancer	0.000245	0.000931	CcSEcCtD
Epinephrine—SLC22A5—lymph node—lung cancer	0.000245	0.0104	CbGeAlD
Epinephrine—Nervous system disorder—Docetaxel—lung cancer	0.000243	0.000922	CcSEcCtD
Epinephrine—Drowsiness—Doxorubicin—lung cancer	0.000242	0.00092	CcSEcCtD
Epinephrine—Tachycardia—Docetaxel—lung cancer	0.000242	0.000917	CcSEcCtD
Epinephrine—Skin disorder—Docetaxel—lung cancer	0.000241	0.000913	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—lung cancer	0.000238	0.000904	CcSEcCtD
Epinephrine—Dizziness—Irinotecan—lung cancer	0.000237	0.000899	CcSEcCtD
Epinephrine—Sweating—Doxorubicin—lung cancer	0.000232	0.000882	CcSEcCtD
Epinephrine—Vomiting—Irinotecan—lung cancer	0.000228	0.000865	CcSEcCtD
Epinephrine—Insomnia—Docetaxel—lung cancer	0.000224	0.00085	CcSEcCtD
Epinephrine—Paraesthesia—Docetaxel—lung cancer	0.000222	0.000844	CcSEcCtD
Epinephrine—Vomiting—Gemcitabine—lung cancer	0.000222	0.000842	CcSEcCtD
Epinephrine—Somnolence—Docetaxel—lung cancer	0.00022	0.000836	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—lung cancer	0.00022	0.000835	CcSEcCtD
Epinephrine—Erythema—Methotrexate—lung cancer	0.000219	0.00083	CcSEcCtD
Epinephrine—Haemoglobin—Doxorubicin—lung cancer	0.000219	0.00083	CcSEcCtD
Epinephrine—Haemorrhage—Doxorubicin—lung cancer	0.000218	0.000826	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—lung cancer	0.000216	0.000822	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000214	0.000812	CcSEcCtD
Epinephrine—Nausea—Irinotecan—lung cancer	0.000213	0.000808	CcSEcCtD
Epinephrine—Nausea—Gemcitabine—lung cancer	0.000207	0.000787	CcSEcCtD
Epinephrine—Vomiting—Cisplatin—lung cancer	0.000207	0.000785	CcSEcCtD
Epinephrine—ADRA2A—lymph node—lung cancer	0.000204	0.00868	CbGeAlD
Epinephrine—Flushing—Doxorubicin—lung cancer	0.000202	0.000766	CcSEcCtD
Epinephrine—Dizziness—Etoposide—lung cancer	0.000197	0.000748	CcSEcCtD
Epinephrine—Arrhythmia—Doxorubicin—lung cancer	0.000194	0.000738	CcSEcCtD
Epinephrine—Dizziness—Paclitaxel—lung cancer	0.000193	0.000733	CcSEcCtD
Epinephrine—Nausea—Cisplatin—lung cancer	0.000193	0.000733	CcSEcCtD
Epinephrine—Mental disorder—Doxorubicin—lung cancer	0.000191	0.000723	CcSEcCtD
Epinephrine—Vomiting—Etoposide—lung cancer	0.000189	0.000719	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—lung cancer	0.000189	0.000719	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—lung cancer	0.000186	0.000707	CcSEcCtD
Epinephrine—Tension—Doxorubicin—lung cancer	0.000186	0.000705	CcSEcCtD
Epinephrine—Vomiting—Paclitaxel—lung cancer	0.000186	0.000705	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000185	0.000702	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—lung cancer	0.000184	0.000698	CcSEcCtD
Epinephrine—Nausea—Etoposide—lung cancer	0.000177	0.000672	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—lung cancer	0.000175	0.000664	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—lung cancer	0.000174	0.000661	CcSEcCtD
Epinephrine—Nausea—Paclitaxel—lung cancer	0.000174	0.000659	CcSEcCtD
Epinephrine—Skin disorder—Methotrexate—lung cancer	0.000173	0.000658	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—lung cancer	0.000173	0.000655	CcSEcCtD
Epinephrine—Palpitations—Doxorubicin—lung cancer	0.000167	0.000635	CcSEcCtD
Epinephrine—Dizziness—Docetaxel—lung cancer	0.000164	0.000622	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—lung cancer	0.000164	0.000621	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—lung cancer	0.000161	0.000613	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—lung cancer	0.000161	0.000612	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—lung cancer	0.00016	0.000608	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00016	0.000608	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—lung cancer	0.000159	0.000602	CcSEcCtD
Epinephrine—Vomiting—Docetaxel—lung cancer	0.000157	0.000598	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000154	0.000585	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—lung cancer	0.000152	0.000575	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—lung cancer	0.000151	0.000573	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—lung cancer	0.00015	0.00057	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—lung cancer	0.000149	0.000567	CcSEcCtD
Epinephrine—Nausea—Docetaxel—lung cancer	0.000147	0.000558	CcSEcCtD
Epinephrine—Insomnia—Doxorubicin—lung cancer	0.00014	0.000531	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—lung cancer	0.000139	0.000527	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—lung cancer	0.000137	0.000522	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000133	0.000506	CcSEcCtD
Epinephrine—Dizziness—Methotrexate—lung cancer	0.000118	0.000448	CcSEcCtD
Epinephrine—Vomiting—Methotrexate—lung cancer	0.000113	0.000431	CcSEcCtD
Epinephrine—Nausea—Methotrexate—lung cancer	0.000106	0.000402	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—lung cancer	0.000102	0.000388	CcSEcCtD
Epinephrine—Vomiting—Doxorubicin—lung cancer	9.83e-05	0.000373	CcSEcCtD
Epinephrine—Nausea—Doxorubicin—lung cancer	9.18e-05	0.000348	CcSEcCtD
Epinephrine—CYP1A2—Metabolism—TYMS—lung cancer	5.34e-06	1.95e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SRC—lung cancer	5.32e-06	1.94e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NQO1—lung cancer	5.31e-06	1.94e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCND1—lung cancer	5.3e-06	1.93e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CXCL8—lung cancer	5.29e-06	1.93e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—EP300—lung cancer	5.29e-06	1.93e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—JUN—lung cancer	5.28e-06	1.93e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTM1—lung cancer	5.27e-06	1.92e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—HRAS—lung cancer	5.26e-06	1.92e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MMP9—lung cancer	5.26e-06	1.92e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	5.25e-06	1.91e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CDKN1A—lung cancer	5.24e-06	1.91e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTEN—lung cancer	5.23e-06	1.91e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	5.22e-06	1.9e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MMP9—lung cancer	5.21e-06	1.9e-05	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	5.2e-06	1.9e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	5.19e-06	1.89e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—VEGFA—lung cancer	5.18e-06	1.89e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTEN—lung cancer	5.18e-06	1.89e-05	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	5.17e-06	1.88e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CASP3—lung cancer	5.15e-06	1.88e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MMP9—lung cancer	5.14e-06	1.88e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL2—lung cancer	5.14e-06	1.87e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—STAT3—lung cancer	5.13e-06	1.87e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CDKN1A—lung cancer	5.12e-06	1.87e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NRAS—lung cancer	5.12e-06	1.87e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—IL6—lung cancer	5.11e-06	1.87e-05	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	5.11e-06	1.87e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTEN—lung cancer	5.11e-06	1.86e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	5.11e-06	1.86e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—AKT1—lung cancer	5.1e-06	1.86e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—AKT1—lung cancer	5.07e-06	1.85e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CASP3—lung cancer	5.07e-06	1.85e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL2—lung cancer	5.06e-06	1.85e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	5.05e-06	1.84e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	5.05e-06	1.84e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—IL6—lung cancer	5.03e-06	1.84e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MDM2—lung cancer	5.03e-06	1.83e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—APOA1—lung cancer	5.02e-06	1.83e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—RAF1—lung cancer	5.01e-06	1.83e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCND1—lung cancer	5.01e-06	1.83e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CYP1A1—lung cancer	5e-06	1.82e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—JUN—lung cancer	5e-06	1.82e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—AKT1—lung cancer	4.99e-06	1.82e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EP300—lung cancer	4.98e-06	1.82e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ERCC2—lung cancer	4.96e-06	1.81e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—ERBB2—lung cancer	4.96e-06	1.81e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EP300—lung cancer	4.94e-06	1.8e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCND1—lung cancer	4.93e-06	1.8e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—JUN—lung cancer	4.92e-06	1.79e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MAPK3—lung cancer	4.9e-06	1.79e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MTOR—lung cancer	4.89e-06	1.78e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	4.89e-06	1.78e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EP300—lung cancer	4.87e-06	1.78e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MMP9—lung cancer	4.86e-06	1.77e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	4.85e-06	1.77e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SRC—lung cancer	4.85e-06	1.77e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTEN—lung cancer	4.84e-06	1.76e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.81e-06	1.75e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SRC—lung cancer	4.8e-06	1.75e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MMP9—lung cancer	4.79e-06	1.75e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—STK11—lung cancer	4.79e-06	1.75e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	4.77e-06	1.74e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MYC—lung cancer	4.77e-06	1.74e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTEN—lung cancer	4.76e-06	1.74e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SRC—lung cancer	4.74e-06	1.73e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—VEGFA—lung cancer	4.72e-06	1.72e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	4.72e-06	1.72e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CXCL8—lung cancer	4.7e-06	1.71e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTEN—lung cancer	4.7e-06	1.71e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	4.69e-06	1.71e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	4.68e-06	1.71e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—STAT3—lung cancer	4.67e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MDM2—lung cancer	4.67e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—HRAS—lung cancer	4.67e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NRAS—lung cancer	4.66e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—EGFR—lung cancer	4.66e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—RAF1—lung cancer	4.66e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—AKT1—lung cancer	4.64e-06	1.69e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—STAT3—lung cancer	4.63e-06	1.69e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NRAS—lung cancer	4.62e-06	1.68e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—VEGFA—lung cancer	4.62e-06	1.68e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EP300—lung cancer	4.61e-06	1.68e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	4.61e-06	1.68e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CG—lung cancer	4.58e-06	1.67e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—STAT3—lung cancer	4.57e-06	1.67e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NRAS—lung cancer	4.56e-06	1.66e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	4.55e-06	1.66e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MTOR—lung cancer	4.55e-06	1.66e-05	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	4.54e-06	1.66e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EP300—lung cancer	4.54e-06	1.66e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CASP3—lung cancer	4.5e-06	1.64e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL2—lung cancer	4.49e-06	1.64e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SRC—lung cancer	4.49e-06	1.64e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—EP300—lung cancer	4.48e-06	1.63e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL6—lung cancer	4.47e-06	1.63e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK3—lung cancer	4.46e-06	1.63e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTP1—lung cancer	4.43e-06	1.62e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	4.42e-06	1.61e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SRC—lung cancer	4.41e-06	1.61e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—lung cancer	4.4e-06	1.61e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCND1—lung cancer	4.38e-06	1.6e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—JUN—lung cancer	4.37e-06	1.59e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	4.37e-06	1.59e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	4.37e-06	1.59e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK3—lung cancer	4.37e-06	1.59e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—POMC—lung cancer	4.36e-06	1.59e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MYC—lung cancer	4.34e-06	1.58e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	4.34e-06	1.58e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—STAT3—lung cancer	4.33e-06	1.58e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NRAS—lung cancer	4.31e-06	1.57e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CAT—lung cancer	4.31e-06	1.57e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MYC—lung cancer	4.3e-06	1.57e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	4.3e-06	1.57e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—APOA1—lung cancer	4.29e-06	1.56e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—STAT3—lung cancer	4.26e-06	1.55e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MMP9—lung cancer	4.25e-06	1.55e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CREBBP—lung cancer	4.25e-06	1.55e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MYC—lung cancer	4.25e-06	1.55e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EGFR—lung cancer	4.25e-06	1.55e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NRAS—lung cancer	4.25e-06	1.55e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	4.24e-06	1.55e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTEN—lung cancer	4.23e-06	1.54e-05	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	4.22e-06	1.54e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EGFR—lung cancer	4.21e-06	1.53e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PIK3CA—lung cancer	4.2e-06	1.53e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ABCB1—lung cancer	4.19e-06	1.53e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CASP3—lung cancer	4.18e-06	1.53e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL2—lung cancer	4.18e-06	1.52e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EGFR—lung cancer	4.15e-06	1.52e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL6—lung cancer	4.15e-06	1.52e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	4.13e-06	1.51e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	4.12e-06	1.5e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—TYMS—lung cancer	4.12e-06	1.5e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.11e-06	1.5e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PIK3CA—lung cancer	4.08e-06	1.49e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTM1—lung cancer	4.07e-06	1.48e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCND1—lung cancer	4.07e-06	1.48e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	4.07e-06	1.48e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—JUN—lung cancer	4.06e-06	1.48e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	4.05e-06	1.48e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EP300—lung cancer	4.03e-06	1.47e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CD—lung cancer	4.03e-06	1.47e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MYC—lung cancer	4.02e-06	1.47e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—lung cancer	4.01e-06	1.46e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—ALB—lung cancer	3.98e-06	1.45e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—lung cancer	3.98e-06	1.45e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MYC—lung cancer	3.96e-06	1.44e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MMP9—lung cancer	3.95e-06	1.44e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	3.94e-06	1.44e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EGFR—lung cancer	3.93e-06	1.43e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTEN—lung cancer	3.93e-06	1.43e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—lung cancer	3.93e-06	1.43e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SRC—lung cancer	3.92e-06	1.43e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CG—lung cancer	3.92e-06	1.43e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—lung cancer	3.91e-06	1.43e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PIK3CA—lung cancer	3.91e-06	1.43e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EGFR—lung cancer	3.87e-06	1.41e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP1A1—lung cancer	3.86e-06	1.41e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	3.83e-06	1.4e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ERCC2—lung cancer	3.83e-06	1.4e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	3.82e-06	1.39e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—STAT3—lung cancer	3.78e-06	1.38e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NRAS—lung cancer	3.77e-06	1.38e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EP300—lung cancer	3.75e-06	1.37e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—HRAS—lung cancer	3.74e-06	1.37e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—POMC—lung cancer	3.73e-06	1.36e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—lung cancer	3.71e-06	1.35e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PIK3CA—lung cancer	3.69e-06	1.34e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—lung cancer	3.66e-06	1.33e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	3.65e-06	1.33e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SRC—lung cancer	3.64e-06	1.33e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CREBBP—lung cancer	3.63e-06	1.32e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	3.61e-06	1.32e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PIK3CA—lung cancer	3.61e-06	1.32e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL6—lung cancer	3.58e-06	1.31e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—lung cancer	3.57e-06	1.3e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	3.55e-06	1.29e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—lung cancer	3.53e-06	1.29e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MYC—lung cancer	3.51e-06	1.28e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—STAT3—lung cancer	3.51e-06	1.28e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CB—lung cancer	3.51e-06	1.28e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NRAS—lung cancer	3.5e-06	1.28e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—lung cancer	3.49e-06	1.27e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTGS2—lung cancer	3.48e-06	1.27e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CD—lung cancer	3.44e-06	1.26e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EGFR—lung cancer	3.44e-06	1.25e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—AKT1—lung cancer	3.43e-06	1.25e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	3.41e-06	1.24e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—HRAS—lung cancer	3.41e-06	1.24e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ALB—lung cancer	3.4e-06	1.24e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—HRAS—lung cancer	3.38e-06	1.23e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	3.36e-06	1.22e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	3.36e-06	1.22e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—HRAS—lung cancer	3.34e-06	1.22e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—AKT1—lung cancer	3.33e-06	1.22e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PIK3CA—lung cancer	3.31e-06	1.21e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—APOA1—lung cancer	3.31e-06	1.21e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—AKT1—lung cancer	3.31e-06	1.21e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—lung cancer	3.3e-06	1.2e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MYC—lung cancer	3.26e-06	1.19e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL6—lung cancer	3.26e-06	1.19e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—lung cancer	3.25e-06	1.18e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—lung cancer	3.25e-06	1.18e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL6—lung cancer	3.23e-06	1.18e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—AKT1—lung cancer	3.19e-06	1.17e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL6—lung cancer	3.19e-06	1.16e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EGFR—lung cancer	3.19e-06	1.16e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—HRAS—lung cancer	3.16e-06	1.15e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—HRAS—lung cancer	3.11e-06	1.13e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTEN—lung cancer	3.03e-06	1.11e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CG—lung cancer	3.02e-06	1.1e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL6—lung cancer	3.02e-06	1.1e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—lung cancer	3.02e-06	1.1e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—AKT1—lung cancer	3.01e-06	1.1e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CB—lung cancer	3e-06	1.09e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—AKT1—lung cancer	2.98e-06	1.09e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	2.98e-06	1.09e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTGS2—lung cancer	2.97e-06	1.08e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL6—lung cancer	2.97e-06	1.08e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—AKT1—lung cancer	2.95e-06	1.07e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—EP300—lung cancer	2.89e-06	1.06e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—lung cancer	2.89e-06	1.05e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—POMC—lung cancer	2.88e-06	1.05e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CREBBP—lung cancer	2.8e-06	1.02e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—AKT1—lung cancer	2.79e-06	1.02e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	2.77e-06	1.01e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HRAS—lung cancer	2.76e-06	1.01e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—AKT1—lung cancer	2.74e-06	1e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—AKT1—lung cancer	2.71e-06	9.87e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—lung cancer	2.68e-06	9.78e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CD—lung cancer	2.66e-06	9.69e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL6—lung cancer	2.64e-06	9.63e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ALB—lung cancer	2.62e-06	9.57e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTEN—lung cancer	2.59e-06	9.46e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HRAS—lung cancer	2.56e-06	9.35e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—EP300—lung cancer	2.47e-06	9.02e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL6—lung cancer	2.45e-06	8.95e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—AKT1—lung cancer	2.44e-06	8.89e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CB—lung cancer	2.32e-06	8.45e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTGS2—lung cancer	2.3e-06	8.37e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.26e-06	8.26e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CA—lung cancer	2.14e-06	7.81e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTEN—lung cancer	2e-06	7.3e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—EP300—lung cancer	1.91e-06	6.96e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CA—lung cancer	1.83e-06	6.67e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—AKT1—lung cancer	1.75e-06	6.38e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—AKT1—lung cancer	1.49e-06	5.45e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.41e-06	5.15e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—AKT1—lung cancer	1.15e-06	4.21e-06	CbGpPWpGaD
